Skip to main content

Table 2 Cohort description

From: Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study

Parameters Categories N % of total
Breed European 154 85.6%
Other breeds 26 14.4%
Gender Intact female 112 62.2%
Neutered female 68 37.8%
History of contraception Yes 76 42.2%
No 18 10.0%
Unknown 86 47.8%
Previous benign mammary lesions Yes 16 8.9%
No 164 91.1%
Parity Nulliparous 15 8.3%
Multiparous 21 11.7%
Unknown 144 80.0%
Multicentricity Multiple FMCs 26 14.4%
Single FMC 154 85.6%
Pathologic tumor size pT <  20 mm 85 47.2%
pT ≥ 20 mm 95 52.8%
Pathologic nodal stage pN+ (nodal metastasis) 101 56.1%
pN0 (no) 20 11.1%
pNX (unknown) 59 32.8%
Distant metastasis M1 (yes) 8 4.4%
M0 (no) 64 35.6%
MX (unknown) 108 60.0%
WHO stage Stage I 45 25.0%
Stage II 23 12.8%
Stage III 104 57.8%
Stage IV 8 4.4%
WHO Histological type Adenosquamous 4 2.2%
Anaplastic 2 1.1%
Comedocarcinoma 50 27.8%
Cribriform 54 30.0%
Mucinous 15 8.3%
Papillary 7 3.9%
Solid 27 15.0%
Tubular 9 5.0%
Tubulopapillary 12 6.7%
Elston and Ellis histological grading system Grade I 10 5.5%
Grade II 82 45.6%
Grade III 88 48.9%
MMEE grading system Grade I 62 34.4%
Grade II 101 56.1%
Grade III 17 9.4%
Lymphovascular invasion LVI+ 110 61.1%
LVI– 70 38.9%
Tumor-associated inflammation Absent to mild 77 42.8%
Moderate to severe 103 57.2%
Estrogen Receptor (ERα) ER+ (ER ≥ 10%) 49 27.2%
ER– (ER < 10%) 131 72.8%
Progesterone Receptor (PR) PR+ (PR ≥ 10%) 13 7.2%
PR– (PR < 10%) 167 92.8%
HER2 Score 0 103 57.2%
1+ 59 32.8%
2+ 18 10.0%
3+ 0 0
Ki-67 High Ki-67 (≥ 20%) 169 93.9%
Low Ki-67 (<  20%) 11 6.1%
CK5/6 CK5/6+ (≥ 1%) 113 62.8%
CK5/6– (< 1%) 67 37.2%